Clinical Trial

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-22; most recent amendment 2025-12-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-30
Trial Details
NCT Number NCT07080216
Lead Sponsor Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions Cervical Cancer
Enrollment 120 participants
Start Date 2025-09-23
Primary Completion 2027-08 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-05